We are pleased to announce that the clinical results of our HLA TGS kits developed by U-GEN’s subsidiary TBG (Xiamen), titled “Application of ONT in Ambiguous Results of the HLA-DPB1 Genotyping,” have been successfully published in the June 2024 issue (Vol. 26, No. 3) of the Journal of Clinical Transfusion and Laboratory Medicine.
The research was conducted by HLA Laboratory, Beijing Red Cross Blood Center. It focuses on analyzing the efficiency, advantages, and mechanisms of the third-generation sequencing (TGS) technology based on the Oxford Nanopore Technology (ONT) platform in resolving ambiguities in HLA-DPB1 genotyping.
The results demonstrate that TGS technology exhibits high accuracy and efficiency in HLA-DPB1 genotyping, significantly outperforming traditional PCR-SBT and next-generation sequencing (NGS) technologies, providing a more reliable method for transplantation medicine.